Real‐world effectiveness of cenobamate in drug‐resistant and ultra‐refractory epilepsy: A multicenter study
Ondřej Strýček, Jana Amlerová, Martin Pail, Jitka Kočvarová, Jana Slonková, Martin Šimčík, Kateřina Stanzelová, Monika Šibalová, Petr Marusič, Milan Brázdil · 2026
Read Real‐world effectiveness of cenobamate in drug‐resistant and ultra‐refractory epilepsy: A multicenter study by Ondřej Strýček, Jana Amlerová, Martin Pail, Jitka Kočvarová, Jana Slonková, Martin Šimčík, Kateřina Stanzelová, Monika Šibalová, Petr Marusič, Milan Brázdil (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13394743.txt.
Description
Ondřej Strýček and co-authors report, in 2026, real-world results for cenobamate in hard-to-treat epilepsy. Five hundred adults at three Czech centres took the drug after many others had failed. Most had ultra-resistant disease with heavy seizure loads. The team tracked seizure cuts, full freedom, side effects, and how long patients stayed on the drug.
After a year, about three in five patients had at least half as many seizures. About one in six were fully free of seizures. Gains shrank as past drug counts climbed, yet held up even in the toughest group. Most patients stayed on the drug at one year. The authors back its use in routine care.
Catalog record
| CREATOR | Ondřej Strýček, Jana Amlerová, Martin Pail, Jitka Kočvarová, Jana Slonková, Martin Šimčík, Kateřina Stanzelová, Monika Šibalová, Petr Marusič, Milan Brázdil |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 62272 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |